Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database - Université d'Angers Accéder directement au contenu
Article Dans Une Revue European Journal of Dermatology Année : 2020

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database

Philippe Celerier
  • Fonction : Auteur
Caroline Dutriaux
  • Fonction : Auteur
Sophie Dalac-Rat
  • Fonction : Auteur

Résumé

Background: Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma. Objectives: To provide an overview of the management of the French Stage III melanoma population after complete lymph node resection prior to new adjuvant therapies. Materials and methods: A subgroup data analysis. Results: Data from 1,835 patients were analysed (15.58% Stage IIIA, 39.24% Stage IIIB, 43.92% Stage IIIC and 1.25% Stage IIID). Superficial spreading melanoma was the most frequent (70.98% in Stage IIIA for whom mutation analysis was performed; BRAF mutation was identified in up to 62% Stage IIIA patients). Sentinel lymph node biopsy was performed in 88.46% of Stage IIIA patients, 42.36% of Stage IIIB, 53.97% of Stage IIIC and 34.78% of Stage IIID. Up to 80% of Stage IIIA patients had no adjuvant treatment follow-up. Ulceration (p = 0.004; RR: 2.98; 95% CI: 1.4-6.3) and age at diagnosis (p = 0.0002; RR: 1.04; 95% CI: 1.02-1.06) were significant predictive factors for survival. Adjuvant interferon-α was administered in up to 13.04% of Stage IIID patients. Conclusion: Only a small number of Stage III melanoma patients were treated with interferon-α in adjuvant settings. New adjuvant therapies are currently having an effect on clinical practice in France, increasing survival and decreasing cost.
Fichier non déposé

Dates et versions

inserm-03710048 , version 1 (30-06-2022)

Identifiants

Citer

Stéphane Dalle, Emilie Varey, Jean-Michel Nguyen, Alain Dupuy, Henri Montaudie, et al.. Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database. European Journal of Dermatology, 2020, 30 (4), pp.389-396. ⟨10.1684/ejd.2020.3848⟩. ⟨inserm-03710048⟩
32 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More